| 1.08 0 (0%) | 05-01 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.36 | 1-year : | 1.59 |
| Resists | First : | 1.16 | Second : | 1.36 |
| Pivot price | 1.08  |
|||
| Supports | First : | 0.91 | Second : | 0.75 |
| MAs | MA(5) : | 1.1 | MA(20) : | 1.06 |
| MA(100) : | 0.88 |
MA(250) : | 0.86 |
|
| MACD | MACD : | 0  |
Signal : | 0 |
| %K %D | K(14,3) : | 52.4 |
D(3) : | 63 |
| RSI | RSI(14): 58.4 | |||
| 52-week | High : | 1.19 | Low : | 0.53 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BFRI ] has closed above bottom band by 47.3%. Bollinger Bands are 54.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.1 - 1.11 | 1.11 - 1.11 |
| Low: | 1.02 - 1.03 | 1.03 - 1.04 |
| Close: | 1.07 - 1.08 | 1.08 - 1.09 |
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Thu, 30 Apr 2026
Equity incentives and director votes at Biofrontera (NASDAQ: BFRI) 2026 meeting - Stock Titan
Thu, 16 Apr 2026
Biofrontera (BFRI) Stock Iron Condor (Investor Interest) 2026-04-16 - Viral Trade Signals - Xã Thanh Hà
Thu, 19 Mar 2026
BIOFRONTERA ($BFRI) Releases Q4 2025 Earnings | BFRI Stock News - Quiver Quantitative
Mon, 09 Mar 2026
Biofrontera Inc. (BFRI) Upgraded to Buy: Here's Why - Yahoo Finance
Thu, 26 Feb 2026
U.S. Patent Office Issues Final Written Decision Finding - GlobeNewswire
Thu, 05 Feb 2026
Biofrontera Inc. (BFRI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 12 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 14.1 (%) |
| Held by Institutions | 23.6 (%) |
| Shares Short | 296 (K) |
| Shares Short P.Month | 151 (K) |
| EPS | -1.04 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.89 |
| Profit Margin | -25.3 % |
| Operating Margin | 26.6 % |
| Return on Assets (ttm) | -28 % |
| Return on Equity (ttm) | -141.4 % |
| Qtrly Rev. Growth | 36.2 % |
| Gross Profit (p.s.) | 2.63 |
| Sales Per Share | 3.57 |
| EBITDA (p.s.) | -0.97 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -1.04 |
| PEG Ratio | 0 |
| Price to Book value | 1.2 |
| Price to Sales | 0.3 |
| Price to Cash Flow | -0.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|